DLST — Dihydrolipoamide Succinyltransferase

DLST — Dihydrolipoamide Succinyltransferase

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4ea;">DLST</th></tr>
<tr><td><b>Gene Symbol</b></td><td>DLST</td></tr>
<tr><td><b>Full Name</b></td><td>Dihydrolipoamide Succinyltransferase</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>14q24.3</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td>[1727](https://www.ncbi.nlm.nih.gov/gene/1727)</td></tr>
<tr><td><b>OMIM</b></td><td>[608835](https://www.omim.org/entry/608835)</td></tr>
<tr><td><b>Ensembl ID</b></td><td>ENSG00000135842</td></tr>
<tr><td><b>UniProt ID</b></td><td>[P36957](https://www.uniprot.org/uniprot/P36957)</td></tr>
<tr><td><b>Associated Diseases</b></td><td>[Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers-disease), Mitochondrial Disorders</td></tr>
</table>
</div>

Overview

DLST — Dihydrolipoamide Succinyltransferase

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4ea;">DLST</th></tr>
<tr><td><b>Gene Symbol</b></td><td>DLST</td></tr>
<tr><td><b>Full Name</b></td><td>Dihydrolipoamide Succinyltransferase</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>14q24.3</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td>[1727](https://www.ncbi.nlm.nih.gov/gene/1727)</td></tr>
<tr><td><b>OMIM</b></td><td>[608835](https://www.omim.org/entry/608835)</td></tr>
<tr><td><b>Ensembl ID</b></td><td>ENSG00000135842</td></tr>
<tr><td><b>UniProt ID</b></td><td>[P36957](https://www.uniprot.org/uniprot/P36957)</td></tr>
<tr><td><b>Associated Diseases</b></td><td>[Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers-disease), Mitochondrial Disorders</td></tr>
</table>
</div>

Overview

DLST (Dihydrolipoamide Succinyltransferase) encodes the E2 (dihydrolipoamide succinyltransferase, also known as oxoglutarate dehydrogenase complex subunit E2) component of the alpha-ketoglutarate dehydrogenase complex (α-KGDH), which is a key rate-limiting enzyme in the citric acid cycle (TCA cycle, also known as Krebs cycle). The α-KGDH complex catalyzes the oxidative decarboxylation of α-ketoglutarate to succinyl-CoA, producing NADH and CO2. This reaction is one of the three irreversible steps in the TCA cycle and represents a critical node linking carbon metabolism to oxidative phosphorylation. DLST has been implicated in Parkinson's disease through genome-wide association studies (GWAS), and α-KGDH dysfunction has been strongly linked to neurodegeneration due to its roles in mitochondrial energy production, reactive oxygen species (ROS) generation, and α-ketoglutarate signaling[@dlstgwas2013][@kgdh2009].

Summary

DLST encodes the E2 subunit of the alpha-ketoglutarate dehydrogenase complex (α-KGDH), a pivotal mitochondrial enzyme that catalyzes the third step of the TCA cycle. α-KGDH is widely recognized as a sensitive marker of mitochondrial dysfunction and is implicated in the pathogenesis of Parkinson's disease, Alzheimer's disease, and other neurodegenerative disorders. GWAS have identified DLST variants associated with increased PD risk, highlighting its relevance to disease susceptibility. The enzyme's function is particularly important in energy-demanding dopaminergic neurons of the substantia nigra, which are selectively lost in PD. α-KGDH deficiency leads to impaired energy metabolism, increased oxidative stress, and disrupted α-ketoglutarate signaling, all of which contribute to neuronal death[@gibson2002][@bjoerke2015].

Normal Function

Alpha-KGDH Complex

The α-ketoglutarate dehydrogenase complex (α-KGDH) is a large multienzyme complex located in the mitochondrial matrix:

The overall reaction:
α-ketoglutarate + CoA + NAD+ → succinyl-CoA + NADH + CO2

Enzyme Properties

DLST protein properties:

• Subunit structure: Forms a 24-mer core in the α-KGDH complex
• Molecular weight: ~48 kDa per subunit
• Catalytic function: Transfers the acyl group from the lipoyl moiety to CoA
• Lipoate binding: Contains lipoyl-lysine domains that are essential for function

Metabolic Roles

α-KGDH functions in several critical metabolic pathways:

Role in Mitochondrial Function

Energy Production

α-KGDH is crucial for mitochondrial ATP production:

• Produces NADH (2.5 ATP equivalent per NADH)
• Links glycolysis to oxidative phosphorylation
• Supports the high energy demands of neurons

Reactive Oxygen Species

The enzyme impacts ROS through:

• NADH production fuels ETC and can increase ROS
• Loss of α-KGDH activity reduces substrate for ROS generation
• α-Ketoglutarate is a cofactor for demethylases affecting antioxidant gene expression

α-Ketoglutarate Signaling

α-Ketoglutarate serves as:

• Co-substrate for dioxygenases (JmjC-domain histone demethylases, TET DNA demethylases)
• Regulator of epigenetic state
• Modulator of hypoxia-inducible factor (HIF) stability

Disease Associations

Parkinson's Disease

DLST is genetically and functionally linked to PD:

Alzheimer's Disease

α-KGDH dysfunction in AD:

Other Neurodegenerative Conditions

• Amyotrophic lateral sclerosis: Altered α-KGDH in motor neurons
• Huntington's disease: Impaired α-KGDH in striatal neurons
• Mitochondrial encephalopathies: DLST mutations can cause severe neurological disease

Expression Pattern

Tissue Distribution

DLST is expressed in most tissues with high energy demands:

• Brain: Particularly high in cortex, hippocampus, cerebellum, and basal ganglia
• Heart: High expression in cardiac muscle
• Liver: Significant expression in hepatocytes
• Kidney: Substantial expression in renal tubular cells
• Skeletal muscle: High expression in muscle fibers

Brain Expression

In the central nervous system:

• Dopaminergic neurons: High expression in substantia nigra pars compacta
• Pyramidal neurons: High expression in cortical and hippocampal regions
• Cerebellar Purkinje cells: Notable expression
• Astrocytes: Lower expression than neurons

Interaction Network

| Partner | Relationship | Function |
|---------|--------------|----------|
| OGDH (E1) | Complex component | α-ketoglutarate dehydrogenase activity |
| DLDB (E3) | Complex component | Dihydrolipoamide dehydrogenase |
| CoA | Substrate | Co-factor for succinyl-CoA formation |
| NAD+ | Co-substrate | Electron acceptor for NADH production |
| α-Ketoglutarate | Substrate | Primary substrate |
| ATP | Regulator | Allosteric inhibitor |
| ADP | Regulator | Allosteric activator |

Therapeutic Approaches

Small Molecule Modulators

Gene Therapy

• Viral vector delivery of DLST to restore expression
• CRISPR-based approaches to correct pathogenic variants

Symptomatic Approaches

• Supportive care for mitochondrial dysfunction
• Antioxidant supplementation

Animal Models

Mouse Models

• Dlsto/o mice: Knockout models show embryonic lethality or severe metabolic defects
• Conditional knockouts: Brain-specific deletion reveals neuronal functions
• Transgenic models: Overexpression of wild-type or mutant DLST

Disease Models

• Cross with MPTP-treated mice to model PD
• Cross with α-synuclein transgenic mice

Key Publications

Molecular Mechanisms

α-KGDH in Dopaminergic Neurons

Dopaminergic neurons in the substantia nigra pars compacta (SNc) are particularly vulnerable to α-KGDH dysfunction due to several factors[@calingan1999]:

Oxidative Stress Pathway

α-Ketoglutarate and Epigenetic Regulation

Beyond its role in energy metabolism, α-ketoglutarate serves as an essential co-substrate for:

This positions α-KGDH as a metabolic integrator of cellular state and gene expression[@ma2019].

TCA Cycle Disruption in Neurodegeneration

The disruption of α-KGDH creates a metabolic bottleneck:

Genetic Basis of DLST in Disease

GWAS Findings

Multiple large-scale GWAS have identified DLST variants associated with Parkinson's disease risk[@dlstgwas2013][@koshy2018]:

| Study | Population | Effect Size | Risk Allele |
|-------|------------|-------------|-------------|
| Nalls et al. 2013 | European | OR = 1.12 | rs11240572 |
| Koshy et al. 2018 | European | OR = 1.08 | rs7535082 |

Known Pathogenic Variants

Rare DLST variants cause severe neurological disease[@blazquez2019][@postler2022]:

• Missense mutations: Loss-of-function variants cause α-KGDH deficiency
• Compound heterozygosity: Two pathogenic alleles cause severe phenotype
• Genotype-phenotype correlation: Severity correlates with residual enzyme activity

Clinical and Therapeutic Implications

Biomarker Potential

DLST and α-KGDH activity serve as biomarkers:

Therapeutic Targets

Multiple approaches target α-KGDH[@ma2019][@patel2014][@mcdonald2017]:

Clinical Trials

• No completed Phase III trials targeting α-KGDH directly
• Several trials testing metabolic modulators in PD and AD
• Trials of CoQ10, lipoic acid, and metabolic cocktails

Research Models

In Vitro Models

• Primary neuronal cultures: Mouse and rat neurons
• iPSC-derived neurons: Patient-specific dopaminergic neurons
• Cell lines: SH-SY5Y, PC12 for mechanistic studies

In Vivo Models

• Dlsto/o mice: Global knockout - embryonic lethal
• Conditional knockouts: Brain-specific deletion
• Transgenics: Human DLST expression in mouse models

Disease Models

• MPTP model: Toxin-induced PD with α-KGDH changes
• 6-OHDA model: Striatal lesion model
• α-Synuclein models: Transgenic mice

Comparison with Other TCA Cycle Enzymes

| Enzyme | Gene | Association | Evidence |
|--------|------|-------------|----------|
| α-KGDH (E1) | OGDH | PD, AD | Strong[@kgdh2009] |
| α-KGDH (E2) | DLST | PD, AD | Strong[@dlstgwas2013] |
| α-KGDH (E3) | DLDB | PD | Moderate |
| PDH | PDHA1 | PD, Leigh syndrome | Strong |
| IDH | IDH1/2 | Glioma, AD | IDH1 in AD |

Future Directions

Knowledge Gaps

Emerging Research

Mechanism Diagram

Additional References

Related Conditions

• [Parkinson's disease](/diseases/parkinsons-disease)
• [Alzheimer's disease](/diseases/alzheimers-disease)
• [Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)
• [TCA cycle alterations](/mechanisms/metabolic-dysfunction)
• [Oxidative stress in neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration)
• [Substantia nigra degeneration](/brain-regions/substantia-nigra)
• [Dopaminergic neuron loss](/mechanisms/dopaminergic-neurodegeneration)

Pathophysiology in Detail

Energy Crisis in Dopaminergic Neurons

Dopaminergic neurons of the substantia nigra pars compacta (SNc) face an "energy crisis" that makes them particularly vulnerable to α-KGDH dysfunction. These neurons have high baseline energy demands due to their pacemaking activity, which requires continuous calcium cycling and ATP-dependent ion pumping. The combination of high energy demand and limited compensatory capacity creates a vulnerability threshold[@schapira2019].

When α-KGDH activity is reduced:

The α-Ketoglutarate Connection

Beyond energy production, α-ketoglutarate serves crucial signaling roles:

Epigenetic Regulation:

• α-Ketoglutarate is an essential cofactor for JmjC-domain histone demethylases
• These enzymes regulate H3K9me3, H3K27me3 marks important for neuronal gene expression
• Loss of α-ketoglutarate leads to epigenetic dysregulation

• TET demethylases require α-ketoglutarate to convert 5mC to 5hmC
• Altered α-ketoglutarate affects DNA methylation patterns
• These changes may persist and contribute to disease progression

• Prolyl hydroxylases use α-ketoglutarate to hydroxylate HIF-α
• Under normal oxygen, HIF is hydroxylated and degraded
• With α-KGDH dysfunction, α-ketoglutarate depletion may affect hypoxia response

Interaction with Other Neurodegeneration Mechanisms

α-KGDH dysfunction intersects with multiple neurodegenerative pathways:

Protein Aggregation:

• Mitochondrial dysfunction can promote α-synuclein aggregation
• Energy stress may impair autophagy of misfolded proteins
• ROS can oxidize proteins, increasing aggregation propensity

• Mitochondrial ROS activates microglia
• DAMPs released from damaged neurons trigger inflammation
• Chronic inflammation further impairs neuronal function

• Energy failure leads to loss of glutamate transporter function
• Extracellular glutamate accumulates
• NMDA receptor overactivation causes calcium influx

Case Studies and Clinical Observations

DLST-Associated Mitochondrial Encephalopathy

Rare cases of DLST mutations cause severe neurological disease[@postler2022]:

Clinical Features:

• Early-onset encephalopathy
• Developmental delay
• Seizures
• Movement disorders
• Elevated lactate

• Reduced α-KGDH activity in fibroblasts
• Elevated α-ketoglutarate in plasma
• Abnormal organic aciduria

Parkinson's Disease Subgroups

Patients with DLST risk variants may represent a distinct PD subgroup:

Characteristics:

• Earlier age of onset
• More prominent gait dysfunction
• Greater executive dysfunction
• Different treatment response

Diagnostic Approaches

Biochemical Testing

Genetic Testing

Imaging

Treatment Strategies

Current Approaches

Metabolic Support:

• CoQ10 supplementation (100-300 mg/day)
• Lipoic acid (300-600 mg/day)
• Thiamine (100-300 mg/day)
• B-complex vitamins

• MitoQ
• PQQ (pyrroloquinoline quinone)
• Creatine

• Levodopa for PD symptoms
• Physical therapy
• Occupational therapy

Investigational Approaches

Enzyme Activation:

• Small molecules to directly enhance α-KGDH activity
• Allosteric activators under development
• Gene therapy approaches

• α-Ketoglutarate supplementation
• Metabolic intermediates
• Anaplerotic agents

Prevention and Risk Reduction

Lifestyle Interventions

Monitoring

• Regular metabolic screening for at-risk individuals
• Genetic counseling for families with DLST variants
• Early intervention when dysfunction is detected

Research Priorities

Short-term Goals

Long-term Goals

Conclusion

DLST encodes the E2 subunit of α-ketoglutarate dehydrogenase complex, a pivotal enzyme linking TCA cycle function to neuronal survival. GWAS and biochemical studies confirm its role in Parkinson's disease susceptibility and progression. The enzyme's position as a metabolic hub makes it an attractive therapeutic target, though significant work remains to translate these insights into effective treatments.

See Also

• [Genes Directory](/genes/)
• [Proteins Directory](/proteins/)
• [Citric acid cycle mechanisms](/mechanisms/citric-acid-cycle)
• [Mitochondrial energy metabolism](/mechanisms/mitochondrial-energy-metabolism)

External Links

• [NCBI Gene: DLST](https://www.ncbi.nlm.nih.gov/gene/1727)
• [Ensembl: ENSG00000135842](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135842)
• [UniProt: P36957](https://www.uniprot.org/uniprot/P36957)
• [OMIM: 608835](https://www.omim.org/entry/608835)